Loading...

Mario Chojkier

TitleProfessor In Residence
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #9111-D
La Jolla CA 92093
Phone858-552-8585
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Fellowship1979Yale University
    Residency1977Yale University
    Residency1975Instituto Nacional de la Salud, Argentina
    Internship 1972Buenos Aires University
    MD, Magna Cum Laude1970Buenos Aires University

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
    NIH/NHLBI R41HL127919Apr 25, 2015 - Mar 31, 2016
    Role: Principal Investigator
    C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS
    NIH/NHLBI R41HL122022Sep 1, 2014 - Aug 31, 2015
    Role: Principal Investigator
    C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS
    NIH/NIDDK R41DK100189Sep 5, 2013 - Aug 31, 2014
    Role: Principal Investigator
    Liver Inflammation and Injury: Molecular Mechanisms
    VA I01BX000525Oct 1, 2010 - Sep 30, 2014
    Role: Principal Investigator
    C/EBP beta Peptides for the Treatment of Hepatic Fibrosis
    NIH/NIDDK RC1DK087031Sep 30, 2009 - Aug 31, 2012
    Role: Co-Principal Investigator
    C/EBP beta SIGNALS HEPATOCYTE PROLIFERATION AND SURVIVAL
    NIH/NIDDK R37DK046971Jul 15, 1993 - May 31, 2013
    Role: Principal Investigator
    C/EBP BETA IN HEPATOCYTE GENE EXPRESSION &PROLIFERATION
    NIH/NIDDK R01DK046971Jul 15, 1993 - Aug 31, 2003
    Role: Principal Investigator
    Hepatic Fibrosis: Molecular Mechanisms
    NIH/NIDDK R01DK038652Jul 1, 1987 - May 31, 2011
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One. 2017; 12(2):e0169310. PMID: 28146577.
      View in: PubMed
    2. Buck M, Solis-Herruzo J, Chojkier M. C/EBPß-Thr217 Phosphorylation Stimulates Macrophage Inflammasome Activation and Liver Injury. Sci Rep. 2016 Apr 12; 6:24268. PMID: 27067260; PMCID: PMC4828658.
    3. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014 Aug; 147(2):377-84.e1. PMID: 24818764.
      View in: PubMed
    4. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15; 370(20):1889-98. PMID: 24725239.
      View in: PubMed
    5. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15; 370(20):1879-88. PMID: 24720702.
      View in: PubMed
    6. Buck M, Garcia-Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, Patch D, Matloff DS, Clopton P, Chojkier M. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology. 2014 Mar; 59(3):1052-9. PMID: 24115225.
      View in: PubMed
    7. Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M. Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. PLoS One. 2012; 7(3):e31516. PMID: 22412837; PMCID: PMC3296686.
    8. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, Abdelmalek M, Bakken A, Renou C, Palmer M, Levine RA, Bhandari BR, Cornpropst M, Liang W, King B, Mondou E, Rousseau FS, McHutchison J, Chojkier M. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012 Feb; 55(2):419-28. PMID: 22006541; PMCID: PMC3779694.
    9. Buck M, Chojkier M. C/EBPß-Thr217 phosphorylation signaling contributes to the development of lung injury and fibrosis in mice. PLoS One. 2011; 6(10):e25497. PMID: 21998664.
      View in: PubMed
    10. Buck M, Chojkier M. A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PLoS One. 2007 Dec 26; 2(12):e1372. PMID: 18159255; PMCID: PMC2137951.
    11. Buck M, Chojkier M. C/EBPbeta associates with caspase 8 complex proteins and modulates apoptosis in hepatic stellate cells. J Clin Gastroenterol. 2007 Nov-Dec; 41 Suppl 3:S295-9. PMID: 17975479.
      View in: PubMed
    12. Buck M, Chojkier M. C/EBPbeta phosphorylation rescues macrophage dysfunction and apoptosis induced by anthrax lethal toxin. Am J Physiol Cell Physiol. 2007 Dec; 293(6):C1788-96. PMID: 17855774.
      View in: PubMed
    13. Ghosh P, Miyai K, Chojkier M. Gastric adenocarcinoma inducing portal hypertension: a rare presentation. World J Gastroenterol. 2007 Feb 14; 13(6):960-3. PMID: 17352032; PMCID: PMC4065938.
    14. Carr RA, André AK, Chen P, Grabowski BA, Chang MS, Locke CS, Williams LA, Chojkier M. The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar). Nephron Clin Pract. 2006; 103(3):c100-5. PMID: 16534233.
      View in: PubMed
    15. Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005 Apr; 39(4 Suppl 2):S143-6. PMID: 15758650.
      View in: PubMed
    16. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology. 2005 Feb; 41(2):237-46. PMID: 15657914.
      View in: PubMed
    17. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol. 2003 Sep; 39(3):437-46. PMID: 12927933.
      View in: PubMed
    18. Buck M, Chojkier M. Signal transduction in the liver: C/EBPbeta modulates cell proliferation and survival. Hepatology. 2003 Apr; 37(4):731-8. PMID: 12668962.
      View in: PubMed